sb 203580 has been researched along with isoquinoline in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (isoquinoline) | Trials (isoquinoline) | Recent Studies (post-2010) (isoquinoline) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 397 | 0 | 211 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, K; Magota, K; Matsui, M; Murafuji, H; Nagahira, A; Nagahira, K; Oikawa, S | 1 |
1 other study(ies) available for sb 203580 and isoquinoline
| Article | Year |
|---|---|
Identification of a novel inhibitor of LPS-induced TNF-alpha production with antiproliferative activity in monocyte/macrophages.
Topics: Activating Transcription Factor 2; Animals; Cell Count; Cell Division; Cell Line; Cyclic AMP Response Element-Binding Protein; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gene Expression Regulation; Imidazoles; Isoquinolines; Leucine; Lipopolysaccharides; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mitogen-Activated Protein Kinases; Monocytes; p38 Mitogen-Activated Protein Kinases; Pyridines; RNA, Messenger; Time Factors; Transcription Factors; Tritium; Tumor Necrosis Factor-alpha | 2001 |